Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATE: Switching to Natalizumab in Relapsing MS
NCT02241785Phase 4Terminated
- Sponsor
- Biogen
- Start
- Sep 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Started Sep 2014; status: terminated.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02241785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241785.